ASH 2018

New data suggest that adding obinutuzumab to ibrutinib in patients with chronic lymphocytic leukemia (CLL) may be effective at improving minimal residual disease (MRD) response rates, especially in patients with low tumor burden after prior ibrutinib therapy.
Researchers report promising findings for patients treated with a venetoclax-rituximab combination regimen in relapsed/refractory chronic lymphocytic leukemia (CLL).
The combination of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab achieved a high rate of undetectable minimal residual disease in previously untreated patients with IGHV-mutated chronic lymphocytic leukemia (CLL).
The ALLIANCE study showed that ibrutinib produces superior progression-free survival to standard chemoimmunotherapy in older patients with chronic lymphocytic leukemia (CLL).
The Bruton’s tyrosine kinase inhibitor acalabrutinib shows promise as a tolerable, effective monotherapy option for patients with previously untreated chronic lymphocytic leukemia.
Researchers evaluated venetoclax plus rituximab versus bendamustine plus rituximab in inducing deep, durable responses in patients with chronic lymphocytic leukemia, as measured by the rate of minimal residual disease.
informCLL registry analysis revealed that prognostic testing patterns in the real-world setting remain suboptimal despite inclusion in National Comprehensive Cancer Network and International Workshop on Chronic Lymphocytic Leukemia guidelines.

Results 1 - 7 of 7

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
  • Please enter your mailing address.

    Address Line 2
    Zip Code